Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Global Business Websites |
     
  3. Contact us |
  4. Sitemap |
  5. Links |
  6. Help
  1. Font size

    Reduce the font size Increase the font size  
 
 

Other Products

Contact us

Product information services

To get more information
about our products,
please send us your inquiries.

Content :

Other products

Sanofi is focused on providing answers for patients in a number of pathologies, including the prevention and treatment of thrombosis and cardiovascular diseases in particular.

 

Thrombosis

Venous Thromboembolism (VTE), is the obstruction of a vein by a blood clot, is the third most common cardiovascular disease in the western world, occurring in about 0.1% of people every year.

Long periods of immobility can result in the development of blood clots. For example, blood clots can occur if you have to stay in bed for a long period of time, such as after an operation on your knee or hip, or during a major illness.

In thrombosis, Sanofi leading medicines are:

  • Plavix® (clopidogrel bisulfate), an antiplatelet agent indicated in the secondary prevention of atherothrombosis-related events. It is commercialized in alliance with Bristol-Myers Squibb. Since 1998, it is estimated that at least 115 million people in 115 countries have been treated with Plavix®.
  • Clexane® (enoxaparin sodium), a low molecular weight heparin indicated in the prevention and treatment of deep vein thrombosis, and the treatment of unstable angina and non-Q-wave myocardial infarction in association with aspirin. Clexane® has been used to treat more than 350 million patients in 100 countries.
    Clexane® is available in:
    • Clexane 80mg/0.8ml prefilled syringe,
    • Clexane 20mg/0.2ml prefilled syringe,
    • Clexane 40mg/0.2ml prefilled syringe,
    • Clexane 60mg/0.6ml prefilled syringe.

Cardiovascular

Cardiovascular disease is one of the main causes of death and acquired disability and that's why it is a major healthcare priority throughout the industrialized world. Sanofi is committed to improving the health of men and women around the globe.

Common Types of Heart Disease

  • Angina
  • Hypertension
  • Atherosclerosis

In cardiovascular, Sanofi top medicines are:

  • Aprovel® (irbesartan) and CoAprovel® (irbesartan hydrochlorothiazide) are major treatments in high blood pressure.Irbesartan is a type of medicine called an angiotensin II receptor antagonist thatblocks the receptors that angiotensin II acts on, and so prevents its actions.
    • Aprovel® available for oral administration as tablets containing 150 mg and 300 mg of irbesartan.
    • CoAprovel® available for oral administration as tablets containing 150mg/12.5mg, 300mg/12.5mg and 300mg/25mg of (irbesartan / hydrochlorothiazide)
  • Cordarone® (amiodaroneHCl) is a member of the drug class group III antiarrhythmics and is used to treat Arrhythmia, Supraventricular Tachycardia, Ventricular Fibrillation and Ventricular Tachycardia. Cordarone® available for oral administration as tablets containing 150mg and200 mg of amiodarone hydrochloride.
  • Tildiem®60mg (Diltiazem) & Mono Tildiem SR 200® / Mono Tildiem® SR 300 (DiltiazemHCl) Bi-Tildiem® 90mg / Bi-Tildiem® 120gm (sustained release Diltiazem) used as Preventive treatment of angina pectoris attacks and Arterial hypertension.
  • Trental® 400 (Oxpentifylline) is used to treat thesymptoms of chronic occlusive arterial disease.

Sanofi portfolio has many other specialties, including:

  • Depakine® (sodium valproate), a reference treatment for epilepsy.
  • Xatral® (alfuzosin hydrochloride), for the treatment of benign prostatic hyperplasia.

In the field of renal pathologies:

  • Renagel® (sevelamer hydrochloride) and Renvela® (sevelamer carbonate) are oral phosphate binders used by chronic kidney disease (CKD) patients on dialysis to treat a condition called hyperphosphatemia, or elevated phosphorus levels, which is associated with heart and bone disease. Renvela® is a second generation, buffered phosphate binder. Renvela® is also approved to control hyperphosphatenmia in CKD adults not on dialysis but with very high blood phosphorus levels.

In biosurgery:

  • Synvisc-One® (hylan G-F 20) are viscosupplements used to treat pain associated with osteoarthritis of certain joints. Synvisc® is a triple-injection product and Synvisc-One® is a next-generation, single-injection product. The principal viscosupplementation market is treatment of pain associated with osteoarthritis of the knee.

Update: April 10, 2014